"Dr. Garnier stressed that the absolute risk of heart attacks in patients taking Avandia was still low -- between 0.43% and 1.85% of patients had heart attacks, according to Dr. Nissen's paper, which was published in the New England Journal of Medicine. Those odds were 43% higher than the rate of heart attacks among patients taking other drugs or a placebo, which ranged from 0.34% to 1.44%.
Dr. Garnier said Dr. Nissen's analysis is only one piece in a body of research that overall shows that Avandia is no riskier for the heart than other diabetes medications. "You cannot look at this in isolation," he said."
Wednesday, May 23, 2007
Glaxo Smith Kline's CEO Dr. Jean-Pierre Garnier offered this valuable perspective on the Avandia controversy today according to the Wall Street Journal: